Cote, Gregory M.

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 165

Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes

Miller, T. A., LeBrasseur, N. K., Cote, G. M., Trucillo, M. P., Pimentel, D. R., Ido, Y., Ruderman, N. B., & Sawyer, D. B. (2005) · Biochemical and Biophysical Research Communications

Cardiac Ischemia and ReperfusionCardiovascular Function and Risk Factors

Cited by 146

A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers

Tolcher, A., Flaherty, K., Shapiro, G. I., Berlin, J., Witzig, T., Habermann, T., Bullock, A., Rock, E., Elekes, A., Lin, C., et al. (2018) · The Oncologist

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 57

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 56

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer

Garcia, A. A., Hays, J. L., Cote, G. M., Becerra, C., Langleben, A., Lau, S. K., Roman, L. D., McCormick, C. C., Richards, D. A., Braiteh, F. S., et al. (2016) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 7